Company
Haisco
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
1
1 still marketed
Novel approvals
1
Approvals since 2021
1
Originals and new uses
Phase 3 trials
34
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Cypsedo approved NovelMay 29, 2026
Drugs in development (0)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
No investigational drugs in Phase 2 or 3 trials under this sponsor name.
Recruiting Phase 3 trials
Largest first.
- A Phase 3 Study Evaluating the Safety and Efficacy of HSK31679 in Patients With MASHPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07581951 · 886 participants (planned) · Start Jun 30, 2026 · Primary completion Jun 30, 2029
Drug: HSK31679; Placebo · For: MASH - Metabolic Dysfunction-Associated Steatohepatitis; NASH (Non-Alcoholic Steatohepatitis)
Sites: Beijing, China
- A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07616375 · 669 participants (planned) · Start Sep 28, 2025 · Primary completion Jan 10, 2029
Drug: HSK31858, tablet · For: Non-cystic Fibrosis Bronchiectasis
Sites: Yixingcun, China
- A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis BronchiectasisPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT06660992 · 669 participants (planned) · Start Sep 30, 2024 · Primary completion Nov 28, 2026
Drug: HSK31858, tablet; Placebo · For: Non-cystic Fibrosis Bronchiectasis
Sites: Guangzhou, China; Yixingcun, China
- A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPDPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07583849 · 376 participants (planned) · Start May 24, 2026 · Primary completion Sep 30, 2027
Drug: HSK39004 Dry Powder Inhaler Simulant; HSK39004 Dry Powder Inhaler-0.75mg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Beijing, China
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANPivotal-lookingRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07390123 · 370 participants (planned) · Start Apr 7, 2026 · Primary completion Dec 2027
Drug: HSK39297; Placebo · For: IgA Nephropathy (IgAN)
Sites: Huangshan City, China; Wuhu, China; Beijing, China · 9 sites in all
Marketed drugs (1)
Newest FDA action first.
- Cypsedo Cipepofol · 2026
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.